Development of an Innovative Health Ingredient From Marine By-products for the Healthy Aging (BRAINBOOSTER)

Abyss Ingredients

Status: Completed

Conditions: Age-related Cognitive Decline; Memory Impairment

Treatments: Dietary Supplement: Placebo; Dietary Supplement: Blue fish hydrolysate

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT04910399

BRAINBOOSTER

Details and patient eligibility

About

This interventional, randomised, placebo-controlled and double-blind study aims to evaluate the effect of a dietary supplementation with a blue fish hydrolysate derived from marine by-products, containing peptides and n-3 polyunsaturated fatty acids, on cognitive performance in a healthy older population, between 60 and 73 years old, with lower memory performance.

Full description

The main objective of this study is to evaluate the efficacy of a dietary supplementation with a hydrolysate derived from marine by-products compared to a placebo on the evolution of episodic memory at 3 months in healthy elderly people with lower memory performance.

The secondary objectives of this study are to evaluate the efficacy of a dietary supplementation with a hydrolysate derived from marine by-products compared to a placebo on the evolution at 3 months of verbal recognition memory, working memory, perceived stress level, biological markers of nutritional and hormonal status in healthy elderly people with lower memory performance. Finally, participants' satisfaction with the product will be assessed.

Participants have to take 4 capsules per day of the hydrolysate containing 770 mg (dose per capsule) or of the placebo for 90 days.

Participants will have a phone screening interview and will attend 5 visits to the Bordeaux University Hospital on the Neuro-Psychopharmacological Research Platform.

Enrollment: 53 patients

Sex: All

Ages: 60 to 73 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Male or female subjects, aged between 60 and 73 years old (including age limits),
• BMI between 20 and 30 kg/m2,
• Not diagnosed with Alzheimer's disease and autonomous,
• 26 < MMSE <= 29,
• PAL TEA > 57,
• Affiliated with a social security plan,
• Able to understand the study and consent,
• Available to come to the 5 visits required for the study,
• Informed and have signed an informed consent.

Exclusion criteria

• Person who has participated in the last 3 months or is currently participating in another clinical trial that may interfere with the evaluation of the primary endpoint (memory).
• Subject consuming food supplements likely to have an effect on memory or within less than 6 months
• Subject consuming high level of Vitamin A and/or Long chain n-3 PUFA evaluated by a food frequency questionnaire
• Restrictive or unbalanced diet (hypocaloric, vegetarian, vegan, ...) self-declared at V0
• Fish consumption more than twice a week
• Allergy to fish
• Life threatening pathology (such as cancer) in remission for less than 1 year or still ongoing,
• Diabetes (type 1 or type 2),
• Cardiovascular disease diagnosed within less that 2 years, with the following exceptions: subjects with controlled (medicated) high blood pressure and/ or controlled (medicated) can be included,
• Personal history of stroke
• Personal history of schizophrenia or other psychiatric disorders
• Ongoing neuroleptic treatment
• Current depressive episode characterized at clinical interview according to the criteria of module A of the MINI (Mini International Neuropsychiatric Interview)
• Unbalanced thyroid disease (treatment modified in the last 6 months),
• For women: hormone replacement therapy started less than 3 months ago or for which the dosage of the treatment has been modified in the last 3 months or whose dosage is likely to be modified during the study
• Chronic inflammatory bowel disease or chronic disorders of intestinal absorption
• Diagnosed inflammatory bowel disease or chronic intestinal absorption disorders
• Current antidepressant treatment or discontinuation within the last 3 months
• Substance abuse or alcoholism within the last 6 months (smoking is allowed)
• General anesthesia in the last 6 months or scheduled in the next 6 months
• Alcohol abuse: more than 2 standard drinks per day,
• Subjects with clinical characteristics that may interfere with the performance of the tests (e.g.: acute visual or hearing impairment)
• Person placed under court protection,
• Person participating in another research study with an exclusion period still in progress ongoing,

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

53 participants in 2 patient groups, including a placebo group

Blue fish hydrolysate

Experimental group

Description:

The test product is a food supplement named BrainBooster in our project. It is presented as a capsule containing a blue fish hydrolysate, containing peptides and n-3 polyunsaturated fatty acids.

Treatment:

Dietary Supplement: Blue fish hydrolysate

Placebo

Placebo Comparator group

Description:

The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.

Treatment:

Dietary Supplement: Placebo